U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07025642) titled 'Comparing Treatments for Overactive Bladder in Taiwan: A Study of Outcomes' on June 03.
Brief Summary: Overactive bladder (OAB) syndrome is a prevalent condition that significantly impairs patients' quality of life. Standard therapeutic strategies include oral antimuscarinics (e.g., solifenacin), beta-3 adrenergic agonists (e.g., mirabegron), and intradetrusor injection of botulinum neurotoxin type A (BoNTA). Despite their clinical utility, these treatments share a common mechanism of action: suppression of detrusor muscle contractility. However, it remains unclear whether such suppression translates to a reduction in the overall me...